METHOD FOR MEASURING POLARIZED FLUORESCENCE EMISSIONS

Abstract: Method for the measurement of polarized emissions in which background emissions are compensated for without the necessity of separating a fluorescing material from a substrate which contributes the background fluorescence. The method is particularly useful in measuring fluorescence from a suspension of cells. The method involves the measurement of polarized fluorescence emissions in a vertical and a horizontal plane at a first wavelength and at a second wavelength. The second wavelength is selected based upon the bathochromic shift of the spectrum of the fluorescence emission of the background fluorescence as compared to the fluorescence of the material being analyzed at each of the wavelengths. From these measurements a factor representing the fraction of the total intensity of fluorescence emission due to background fluorescence is determined from which the intensity of the vertically and horizontally polarized emission intensities due to background fluorescence is derived. The derived polarization emission intensities are then deducted from the vertically and horizontally polarized emission intensities obtained at the first wavelength to obtain polarized emission intensities due solely to the material being analyzed. The method of the present invention is particularly adapted for the measurement of polarized fluorescent emissions from suspensions of cells in a substrate which, which substrate contributes background fluorescence.

Description: METHOD FOR MEASURING POLARIZED FLUORESCENCE EMISSIONS Field of the Invention This invention relates to a method for the measurement of polarized fluorescence emissions and more particularly to the use of such method to determine polarization values in viable lymphocytes for the detection of diseases in human and animal bodies. Background of the Invention Many diseases occurring in humans and animals can be detected by the presence of foreign substances or antigens in the blood which are produced as a result of the body's defenses against the disease. Detection of these antigens would appear to provide a diagnostic and treatment tool which is particularly suited for the early detection and treatment of the particular disease or condition which produces the antigen. However, any such procedure must be reliable, reproducible and sensitive and any such procedure should be able to be carried out by persons of ordinary skill and training in laboratory sciences and procedures. Preferably, such procedures should lend themselves to instrumentation and automation. We have developed and reported one procedure for the early detection of cancer which is based upon the measurement of changes in the structuredness of the cytoplasmic matrix of living lymphocytes when exposed to cancer antigens. L. Cercek, B. Cercek, C. I. V. Franklin, "Biophysical Differentiation between Lymphocytes from Healthy Donors, Patients With Malignant Diseases and Other Disorders," Brit. J. Cancer, Vol„ 29, 345 (1974) ; L. Cercek, B. Cercek, "Application of the Phenomena of Changes in the Structuredness of Cytoplasmic Matrix (SCM) in the Diagnosis of Malignant Disorders: A Review," Europ. J. Cancer, Vol. 13,903-915 (1977). In accordance with our procedure we separate a sub-population of SCM- responding lymphocytes from a sample of blood and incubate these lymphocytes with an antigen extracted from a general pool of various malignant tissues or with an antigen extracted from tissue containing a specific type of malignancy. If the blood sample donor is afflicted with a malignancy there will be a characteristic SCM-response exhibited by the lymphocytes after incubation with the cancer associated antigen which can be differentiated from the SCM- response of lymphocytes from donors not afflicted with malignancy. Similarly if the donor is afflicted with the same type of malignancy as that from which the specific tissue antigen was extracted, a characteristic SCM-response will be exhibited which is distinguished from the SCM-response of lymphocytes derived from donors who are not afflicted with that type of malignancy. Thus the SCM-test procedure can be utilized both as a screening test for cancer and as a specific diagnostic test for cancer. Expanding on these results we have found that the SCM-test for cancer can be applied with equivalent results to other types of antigen producing diseases such as, for example, viral and bacterial infections, determination of allergenic reactions, tissue typing, and monitoring allograft reje.ction. The presence of other antigen producing diseases and conditions of the body will not interfere and indeed, a patient afflicted with more than one type of antigen producing disease can be tested for a multiplicity of such diseases simply by running separate tests using for each test an antigen derived from the diseases or conditions being tested for. The SCM-response of the lymphocytes, is most conveniently measured by fluorometric techniques and more particularly by measuring the intracellular fluorescein fluorescence polarization of the lymphocytes. This is accomplished by introducing fluorescein into the cell and measuring the horizontal and vertical components of emitted fluorescence due to excitation of the cell by an energy source,such as blue light. Lymphocytes testing positively to an antigen will exhibit a substantial decrease in fluorescence polarization value as compared to unstimulated control lymphocytes if the donor is afflicted with the disease or condition which produced or which is associated with the antigen against which the lymphocytes were tested. On the other hand, lymphocytes from donors who are not afflicted with the antigen producing disease or condition, will not exhibit a significant decrease in their polarization value after contact with that antigen, indicating a negative SCM-response. Fluorescein molecules are introduced into the lymphocytes being tested by forming a suspension of the test lymphocytes in a substrate solution of fluorogenic agent such as fluorescein diacetate (FDA) in sterile complete phosphate buffered saline solution. The FDA permeates the cell membrane and is converted to fluorescein molecules by enzymatic hydrolysis. Fluorescence measurements are taken on the suspension which is then filtered and fluorescence measurements taken on the filtrate. The filtrate emissions are deducted as background fluorescence from the total emissions of the suspension to arrive at the emission intensity for the lymphocytes. However, the time between recording the suspension emission and carrying out the filtration step must be kept to a minimum in order to avoid erroneous results. Considerable reliance is placed on the skill of the operator to ensure that the filtration step is properly carried out. Summary of the Invention The present invention, which is described in connection with fluorescence emission measurements of cell suspensions but which is applicable to any fluorescing material where background fluorescence is a problem, provides an improved method for measuring and recording the vertical and horizontal components of fluorescence emissions including compensating for background fluorescence without physically separating the fluorescing material from the substrate causing the background fluorescence. The background fluorescence, such as may be due to leakage of a fluorogenic agent, such as fluorescein, from the lymphocytes into the substrate in which they are suspended, is compensated for in a single measurement. The necessity of a filtration step to measure the background emission is eliminated. Errors due to time lags between measurements and the multiple handling of the suspension are eliminated. The measurement technique is readily automated thus making the procedure easier to use and more reliable. In accordance with the present invention, vertically and horizontally polarized fluorescence emissions are measured at a first wavelength and at a second wavelength. The second wavelength is determined by the bathochromic shift of the emission spectra due to background fluorescence emissions. The total fluorescence emission at each of the wavelengths are reduced to a factor representing the fraction of the total intensity of the fluorescence emissions at the first wavelength due to background fluorescence. Utilizing this factor, the vertically and horizontally polarized emission intensities due to background fluorescence at the first wavelength are derived and deducted from the polarized total fluorescence emission intensities to obtain the vertically and horizontally polarized intracellular fluorescence emission intensities which are used to calculate the polarization value of the emitted fluorescence. Fluorescence measurements are preferably carried out in a fluorescence spectrophotometer equipped with a polarization filter for polarizing the excitation energy and a second polarization filter which is movable between a vertical and a horizontal position for polarizing the emmissions passing the vertical and horizontal components of the emitted fluorescence to the photodetection system. Although the spectrophotometer may be equipped with a single photodetector and with means for sequentially measuring the emissions at two different wave lengths, it is preferred that the spectrophotometer be equipped with at least two photo- multipliers so that emissions at two wave lengths can be measured simultaneously. Utilizing the method of the present invention the background fluorescence due to extracellular fluorescence can be automatically compensated for and the separate filtration step thereby eliminated. By utilizing the method of the invention the level of experience, skill and technique required to properly derive the horizontal and vertical fluorescence emission intensities from a lymphocyte suspension are substantially reduced and simplified and may be carried out within the spectrophotometer itself making the above-described SCM-test method available for routine use in clinical laboratories. Other aspects and advantages of the present invention will become apparent from the following detailed description taken in conjunction with the drawings. Brief Description of the Drawings FIG 1 is a flow chart of the SCM-test procedure: and FIG 2 is a schematic diagram of the fluorescence spectrophotometer arrangement utilized for measurement of the SCM-response of the lymphocyte suspension. Detailed Description of the Invention The SCM-test for the detection of cancer and other antigen producing diseases and body conditions is based upon the measurement of changes in the physical state of organization of the cytoplasmic matrix in living cells after incubation with an antigen produced by the disease or body condition being tested for. The term "structuredness of the cytoplasmic matrix" or SCM, is used to describe the physical state of organization of the cytoplasmic matrix at the molecular level. Studies on the mechanisms of SCM-changes revealed that on excitation at 470 nm or 442nm the intracellular fluorescein fluorescence polarization at 510nm or 527nm respectively reflects "structural changes in the mitochondria (SCM)" denoting their transitions from the resting, orthodox conformation into the active, ATP- generating, condensed conformation and vice versa. (L. Cercek & B. Cercek, 1979, Biophysics.J;Vol. 28, 403- 412) . Such changes in the SCM are measurable in a certain sub-population of lymphocytes found in peripheral blood. As reported by the Cerceks, Europ. J. Cancer, supra, human and animal responding lymphocytes from donors afflicted with cancer exhibit differential SCM-responses to phytohaemagglutinin and to cancer basic proteins and antigens derived from specific types of malignant tissue as compared to SCM- responding lymphocytes from patients not afflicted with malignancies. As reported the test is useful both as a screening test and as a specific diagnostic tool. Using the same procedures as reported, the SCM-test has been expanded to other antigen producing diseases and body conditions such as the determination of allergenic reactions to various substances, the detection and determination of viral and bacterial infections and the like. As used in connection with the SCM-test, the term "antigen" is used in its broadest sense to designate any foreign disease or condition related substance, which evokes the SCM-response in SCM- responding lymphocytes. In accordance with the test procedure as shown in FIG.l, a sample of peripheral blood is drawn from a donor and is collected in a heparinized tube. After collection the peripheral blood is treated with iron powder or carbonyl-iron powder and then placed on a magnet to effect separation of the phagocytic cells along with the iron powder from the blood sample. A portion of the blood sample is then transferred to a multi-gradient density solution and centrifuged to effect the separation of the SCM-responding lymphocytes from other blood components based upon their densities in the multi-gradient solution. After separation and washing a portion of the SCM-responding lymphocytes are retained as a control and other portions are stimulated by incubation with antigens derived from or associated with the disease or condition being tested for. The SCM-response of the lymphocytes is determined by measuring the fluorescence polarization of the lymphocytes after admixture with a suitable fluorogenic agent, such as by forming a suspension of the lymphocytes in a solution of fluorescein diacetate (FDA) in phosphate buffered saline, to effect penetration of the lymphocytes by the fluorogenic agent. In the case of the preferred fluorogenic agent FDA, the FDA molecules which are converted into fluorescein molecules within the cell by enzymatic hydrolysis. The fluorescein molecules fluoresce when exposed to excitation energy in the form of vertically polarized light. SCM-response is indicated by the level of change of the polarized intracellular fluorescein polarization value of SCM-responding lymphocytes after stimulation with an antigen as compared to polarization value of a control suspension of the lymphocytes. In accordance with the SCM-test procedure the polarization value (P) of a lymphocyte suspension is obtained by exciting the suspension with a source of light which has been polarized in the vertical plane. The fluorescence emissions from the suspension are also polarized and measurements of fluorescence emissions are made in the vertical plane and in the horizontal plane perpendicular to the vertical plane- These intensities, hereinafter referred to as Iγ for the vertical fluorescence component and I H for the horizontal fluorescence component are utilized to calculate the polarization value (P) for the suspension in accordance with the following formula: (1) P = I y - G x IJJ/I V + G x I H : where Iγ and IJJ are polarized fluorescence intensities in the vertical and horizontal planes respectively and G is a correction factor for the unequal transmission of the horizontal and vertical components of the polarized energy through the optical system of the particular equipment used. The value of G is determined by dividing the vertical fluorescence intensity by the horizontal fluorescence intensity emitted from a filtrate solution, or from a 10~ 7 M solution of fluorescein in phosphate buffered saline which has been excited with horizontally polarized light at the same wavelength as the vertically polarized exciting light. Th# P value of the stimulated lymphocyte suspension is then compared with the P value of an unstimulated control suspension of lymphocytes from the same donor and the percent change of stimulated to unstimulated lymphocytes is an indication of the SCM- response to an antigen. To ensure reproducibility of results, using FDA as the fluorescing agent, the pH of the FDA substrate solution should be maintained at or slightly above 7.4 and the osmolality of the solution should be held to within ±1% of the isotonic value of 0.330 osm/kg. The selection of the excitation and the emission wavelengths is dependent upon the spectra of the lymphocyte/fluorogenic agent suspension. Changes in SCM-response are observed at specific combinations of excitation and emission wavelengths which are dependent upon fluorogenic agent employed. For example, using FDA as the fluorogenic agent the SCM response of the lymphocyte suspension is observed at the emission wavelength of 510nm and the excitation wavelength of 470nm or at the emission wavelength of 527nm and the excitation wavelength of 442nm. A major problem with the use of the fluorescence polarization technique to measure SCM-response of lymphocytes resides in the extracellular fluorescence background which can adversely affect test results unless compensated for. Thus in the case of FDA as the fluorogenic agent, while a substantial portion of the fluorescein molecules formed as a result of enzymatic hydrolysis are retained in viable cells, some fluorescein molecules do leak out of the cells into the substrate solution and substantially add to the b ackground fluorescence of the substrate solution resulting in loss of sensitivity and erroneous results. In accordance with the SCM-test procedure as practiced prior to this invention the lymphocyte suspension was filtered about four to seven minutes after recording the vertical and horizontal components of the fluorescence emissions of the cell suspensions and the vertical and horizontal components of the fluorescence emissions from the filtrate as well as the length of time of the filtration step were recorded. The fluorescence measurements were extrapolated to the half-time of the filtration step and subtracted from the vertical and horizontal fluorescence intensities of the suspension to obtain the vertical and horizontal fluorescence polarization intensities for the lymphocytes themselves. The filtration step can introduce errors into the SCM-test results. For example undue delay in carrying out the* filtration step can adversely affect the readings since the intensity levels are dependent on the time of FDA hydrolysis. In addition, the extra handling of the suspension and the filtration step itself, if not properly carried out, can result in damage to the lymphocyte membranes. This may result in the release of abnormal amounts of intracellular fluorescein into the filtrate, thus causing higher than normal background readings and a resultant reduction in test sensitivity and/or erroneous results. In addition the filtration step requires a kinetic extrapolation to arrive at fluorescence intensities which, if not carried out properly, may lead to the introduction of a bias or error into the SCM-test results. The spectrum of intracellular fluorescein fluorescence, that is the fluorescence from within the cell, and the spectrum of background and extracellular fluorescein fluorescence are bathochromically shifted with respect to one another. Accordingly, the background and the intracellular fluorescence emissions can be regarded as originating from two different fluorophores. On this basis and in accordance with the invention, a method has been developed for measuring the vertical and horizontal polarized fluorescein fluorescence emissions at two wavelengths; at a first wavelength selected for the measurement of the intracellular fluorescence emissions and at a second wavelength within the range of wavelengths determined by the bathochromic shift. The background fluorescence intensity is determined without the necessity of a separate filtration step. The method of the present invention, which can be analyzed and expressed mathematically thus lends itself to automated methods for determining the background fluorescence emissions from a suspension of lymphocytes. As used hereinafter the terms "background" and "extracellular" will be used interchangeably when referring to fluorescence emissions. In accordance with the method of the invention the horizontal and vertical components of the fluorescence emissions from a suspension of SCM-responding lymphocytes which have been treated with a fluorogenic agent and exposed to excitation energy are measured and recorded at the first wavelength and at the second wavelength. Preferably this is accomplished simultaneously by the use of more than one photomultiplier as will be described in more detail in connection with FIG 2. The intensities may also be measured and recorded alternately between the two wavelengths. With respect to the first and the second wavelength, we have found that with fluorescein fluorescence the second wavelength is between about 5 and about 10 nm higher than the first wavelength. The total intensity of the fluorescence emissions at the first wavelength and the second wavelength is determined as the sum of the vertically and horizontally polarized fluorescence emissions at each of the first and second wavelengths in accordance with the following relationship: < 2 > ^otal = I V + 2 ^H X G > where Iy and IJJ are the vertically and the horizontally polarized fluorescence emission intensities and G is a correction factor for the unequal transmission of the horizontal and vertical components of the polarized light through the optical system of the particular equipment used. A factor representing the fraction of said total intensity of said fluorescence emission due to extracellular fluorescence, is then determined by the relationship: K, (3) F = K b ~ K a where K^ is 1.135, K a is 1.048 and Q denotes the total intensity at the second wave length divided by the total intensity at the first wave length. K a is a constant for the equipment used and is the mean value of actual measurements on the equipment of fluorescence intensities at the first and second wavelengths for filtrates of lymphocyte suspensions. K j -, which is a constant for the equipment utilized, is the mean value of the intracellular fluorescence intensity at the second wavelength divided by the intracellular fluorescence intensity at the first wave length. These values are determined for each fluorescence spectrophotometer and for each wavelength pair utilized in the test procedure. In the embodiment of the invention set forth in the examples, the first wave length (1^) is 510 nm. A bathochromic shift of 5nm is selected so that the second wavelength (1 2 ) is 515 nm. The extracellular fluorescence intensity in the vertical and horizontal 5 planes is then derived by the following relationships: (4) I vf - JLM. X F 10 1 + 2 (1 - P., / 1 + P k ) (5) I Hf = ±i-Il x F 15 ( 2 + __________**) x G 1 - P k 20 where I V f and I V f are the extracellular intensities at the first wavelength (1 ] , If is the total suspension intensity at wavelength (l ) , F ^s the factor developed in (2) above, G is a correction factor for the unequal transmission of the horizontal and 25 vertical components of the polarized light through the optical system of the particular equipment used and P k is an extracellular fluorescence polarization value constant derived by the relationship: 30 p -^V filtrate " G x I H filtrate „ k I + G X I 35 V filtrate H filtrate Using fluorescein as the fluorogenic agent, the value of P^ has been experimentally determined to be 0.0254 at 27 β C for lymphatic suspensions. The extracellular intensities for the vertical and 40 horizontal fluorescent intensities, Iγf and I jj f, are subtracted from the total vertical and horizontal fluorescence emission intensities to arrive at the vertical and horizontal intensities for the intracellular fluorescence emissions used in (JL) above to calculate P. As mentioned above the mathematical analysis lends itself to automation so that the entire analysis can be done within the fluorescence spectrophotometer or its ancillary equipment and corrected for in the final output signal. Referring to FIG 2 there is a schematic illustration of a spectrophotometer arrangement used for the measurement of SCM on cell suspensions in accordance with the present invention wherein the excitation source 10 is a suitable light source such as a Xenon lamp. Suitable means such as an optical filter or as shown, an excitation monochromater 12 is disposed in the excitation light path for passing light at a selected excitation wavelength to a fixed polarization filter 14 which transmits only vertically polarized light to the sample lymphocyte/fluorescein suspension 16. Upon exposure to the vertically polarized excitation light the fluorescein molecules fluoresce and the fluorescence emission is directed through a second polarization filter 18 which is fitted with an automatic filter position changer for rotating the orientation of the polarization axis between a vertical and a horizontal plane. The fluorescence emission being thus divided into a vertical and horizontal component then passes through wavelength selection means such as optical filters or as illustrated a pair of emission monochromators 20 and 22, one of which is selected to pass only light at the first wavelength (1;L) and the other to pass light at the second wavelength (1 2 ) . A pair of photodetectors 24 and 26 are placed in the light path of the emission monochromaters 20 and 22 respectively and the output from the photodetectors is fed to amplifier 28. The output from amplifier 28 is fed through a microprocessor 30 for performing the necessary mathematical functions to account for extracellular fluorescence as described above and the output therefrom is sent to a printer 32 for recording the computed intracellular fluorescein fluorescence polarization values. The spectrophotometer utilized for SCM measurements should be one of high sensitivity and stability and should be able to compensate for fluctuations in the intensity of the excitation light since the intensity of the polarized fluorescence is recorded as a function of time and since the bulk concentration of fluorescein in the SCM measurements is only of the order of 10" 9 M to 10 -1 0 M. Also, broad band filter instruments cannot be used in the SCM measurements since the excitation and emission polarization spectra of the lymphocytes show that changes in the SCM can be detected only within a narrow wage length region. The spectrophotometer must also be fitted with a thermostatically controlled cuvette holder since the fluorescein in polarization values are highly temperature dependent (e.g., about 3% per °C) and to ensure the reproducibility of results the temperature of the sample should be closely controlled, i.e. plus or minus 0.2 °C. As illustrated in Fig. 2 the fluorescence spectrophotometer arrangement is provided with a pair of photodetectors (24 and 26) for measurement of the vertical and horizontal fluorescence intensity components at the first wavelength and at the second wavelength. However, if desired, as many as four photodetectors can be utilized so that a separate photodetector is dedicated to the horizontal and vertical intensity polarized components of fluorescence at each of the two wavelengths being measured. Alternatively, a single photodetector may be utilized to measure the horizontally and the vertically polarized components of fluorescence. Also single means such as a filter designed to alternately pass fluorescence at the first wavelength and the second wavelength may be employed in place of two filters or monochromaters. Example SCM-responding lymphocytes w ere separated from samples of peripheral blood of donors in accordance with the method described in our publication in Europ. J. Cancer, supra, by layering a sample of the blood from which the phagocytes had been removed on a Ficoll- Triosil density gradient solution having a density of 1.081g/cm 3 at 25 β C and an os olality of 0.320osm/kg followed by centrifugation at 550 g AV at 20 β C. In accordance with the SCM-procedure for cancer testing, an aliquot of lymphocytes was exposed to phytohaemagglutinin (P *HA) and a second aliquot of lymphocytes from the same sample were exposed to an extract comprising pooled proteins from a variety of malignant tissue, referred to as cancer basic protein (CaBP) . In accordance with our test method the ratio of the polarization value of an aliquot of lymphocytes incubated with CaBP to the polarization value of an aliquot of lymphocytes from the same donor incubated with PHA is an indication of the presence or absence of cancer in the donor. This ratio, referred to as the SCM response ratio (RR) has been found to have a mean value of between about 1.1 to about 1.8 in healthy donors as compared to an RR of between about 0.5 to about 0.95 for patients with malignant disorders. After incubation with the CaBP antigen and formation of the lymphocyte/FDA suspension in accordance with our method as reported in the Europ. J. Cancer, cited above, polarization values for the lymphocyte suspensions were determined on a Perkin- Elmer fluorescence spectrophotometer, model MPF-4 by our reported method in which the total polarized fluorescence emission intensities of the lymphocyte suspension were measured in the horizontal and vertical plane followed by filtration and measurement the polarized fluorescence emission intensities of the filtrate in the horizontal and vertical planes to compensate for the extracellular fluorescence. The excitation wavelength was 470nm and the first emission wavelength was 510nm. Prior to the filtration step, however, the fluorescence emissions from each of the samples were measured an the same equipment at a second emission wavelength of 515 nm. Using the method of the present invention to compensate for background fluorescence polarization values (P) and the SCM response ratios were calculated. These results are compared with the polarization values and the response ratios of the same suspensions obtained by the standard technique in the following table in which the polarization values and the SCM response ratios obtained by the method of the invention are listed in the column entitled "BSM Technique" and the results obtained by the standard technique are in the column entitled "Standard Technique". Table Standard Technique BSM Technique No. Antigen P RR P RR 1 PHA 0.154 0.128 CaBP 0.210 1.36 0.180 1.41 PHA 0.137 0.122 CaBP 0.195 1.42 0.189 1.55 PHA 0.140 0.133 CaBP 0.195 1.39 0.189 1.35 PHA 0.163 0.161 CaBP 0.208 1.28 0.183 1.14 PHA 0.145 0.170 CaBP 0.202 1.39 0.215 1.27 PHA 0.201 0.215 CaBP 0.152 0.76 0.160 0.74 PHA 0.202 0.208 CaBP 0.158 0.78 0.164 0.79 8 PHA 0.202 0.196 CaBP 0.161 0.80 0.164 0.84 The agreement between the polarization values and the SCM response ratios obtained using the Standard Technique involving a filtration step and the method of the invention in which filtration is eliminated are within acceptable limits of accuracy predicted by an error propagation analysis. It will be noted that samples 1-5 have SCM resolution ratios on the order of 1.15 and above which indicates an absence of cancer in the donor. On the other hand the SCM resolution ratios in samples 6-8 are all well below 1.0 indicating that the donor is afflicted with cancer. These results are confirmed by actual diagnosis. Utilizing the method of the present invention we have achieved a fluorescence measurement technique which provides at least equivalent results to the standard technique employed prior to this invention for the determination of SCM-responses of cells and we have eliminated the necessity of a separate filtration step and the problems attendant therewith to compensate for extracellular fluorescence. Although described in connection with the SCM- test,it will be understood that the method of the invention may be applied to any procedure involving the measurement of polarized fluorescence emmissions from material in a substrate which contributes background fluorescence and in which the background flourescence emissions are bathochromically shifted with respect to the emissions to be measured. While the invention has been described and illustrated herein with reference to certain embodiments thereof, it is to be understood that it may be otherwise embodied within the scope of the appended claims.

Claims: CLAIMS 1. In a method for testing a sample of blood of a donor for the presence of a condition or disease in the body of the donor, said procedure based upon the response of lymphocytes separated from a sample of the donors blood to contact with a substance selected from mitogens and antigens associated with the condition or disease being tested for, the lymphocyte.response being indicated by changes in the structuredness of the cytoplasmic matrix of said lymphocytes sensitized to said substance as a result of the presence of said disease or condition in the donor, said change in the structuredness of the cytoplasmic matrix of said lymphocytes being measured by the polarized intracellular fluorescence of said lymphocytes, the improvement comprising measuring horizontally and vertically polarized fluorescence emissions from a suspension of lymphocytes in a substrate, said measurements being taken at a first wavelength and at a second wavelength within the range of wavelengths determined by the bathochromic shift of said fluorescence emission spectrum due to extracellular fluorescence emissions ,obtaining therefrom the total fluoresence emission of said suspension at each of said wavelengths, determining a factor representing the fraction of said total intensity of said fluorescence emission due to extracellular fluorescence, deriving therefrom the vertically and horizontally polarized emission intensities of said extracellular fluorescence, deducting said extracellular intensities from said vertically and horizontally polarized emission intensities measured at said first wavelength to obtain the vertically and horizontally polarized emission intensities due to intracellular fluorescence and thereafter applying said intracellular fluorescence emission intensities to calculate the polarization value of said lymphocytes in said suspension. 2. The method of claim 1 wherein said fluorescence emission spectrum due to extracellular fluorescence emissions is bathochromically shifted between about 5nm and about lOnm with respect to said intracellular fluorescence emissions. 3. The method of claim 1 wherein said first wavelength is 510nm and said second wavelength is selected to be between 515nm and 520nm. 4. The method of claim 3 wherein said second wavelength is 515nm. 5. The method of claim 1 wherein said first wavelength is 527nm and said second wavelength is selected to be between 532nm and 537nm. 6. The method of claim 5 wherein said second wavelength is 532nm. 7. The method of claim 1 wherein said total intensity of the fluorescence emissions at said first wavelength and at said second wavelength is determined by the sum of the vertically and horizontally polarized fluorescence emissions at each of said first and second wavelengths in accordance with the following relationshi : ^otal = v + 2( I H x G) wherein, Iy and I H are the vertically and the horizontally polarized fluorescence emission intensities and G is a correction factor for the unequal transmission of said vertically and said horizontally polarized fluorescence emissions through an optical system of a fluorescence measuring instrument. 8. The method of claim 1 wherein said factor (F) representing the fraction of said total intensity of said fluorescence emission due to extracellular fluorescence, is determined by the relationship: K\ - Q F = wherein, K a is the mean value of the intracellular fluorescence intensity at said second wavelength divided by the intracellular fluorescence intensity at said first wavelength, K j -, is the mean value of actual measurements of extracellular fluorescence emission intensities at said first and said second wavelengths for filtrates of lymphocyte suspensions and K a and Kj-, are constants for the particular instrumentation utilized. 9. The method of claim 1 wherein said vertically polarized emission intensity of said extracellular fluorescence is derived according to the relationship: F Iyf = ( 1) x 1 + 2 (1 - P. / 1 + P. ) where Iyf ^s the vertically polarized extracellular intensity at said first wavelength, I(H) is the total intensity of said fluorescence emissions at said first wavelength, F ^s said factor representing the fraction of said total intensity of said fluorescence emission due to extracellular fluorescence and P k is a constant derived from the relationship: ~ filtrate " G Z H filtrate ? k - τ v filtrate + G X H filtrate _» where Iy filtrate -- s tne vertically polarized fluorescence emission intensity of said fluorogenic substrate from which said lymphocytes have been filtered, I H filtrate ---- the horizontally polarized fluorescence emission intensity of said fluorogenic substrate from which said lymphocytes have been filtered and G is a correction factor for the unequal transmission of said vertically and said horizontally polarized fluorescence emissions through an optical system of a fluorescence measuring instrument. 10. The method of claim 9 wherein P^ is 0.0254 at 27 * C and said fluorogenic substrate is fluoroscein diacetate. 11. The method of claim 1 wherein said horizontally polarized emission intensity of said extracellular fluorescence is derived according to the relationship: I ( 1} X F X Hf = 1 + P. ( 2 + κ ) x G X - P k where I jj is the horizontally polarized extracellular intensity at said first wavelength, I(ii) is the total intensity of said fluorescence emissions at said first wavelength, F is said factor representing the fraction of said total intensity of said fluorescence emission due to extracellular fluorescence and P is a constant derived from the relationship: X V filtrate " G x X H filtrate ?k - X V filtrate + G x X H filtrate where Iy filtrate -- s the vertically polarized fluorescence emission intensity of said fluorogenic substrate from which said lymphocytes have been filtered, I H filtrate -- s the horizontally polarized fluorescence emission intensity of said fluorogenic substrate from which said lymphocytes have been filtered and G is a correction factor for the unequal transmission of said vertically and said horizontally polarized fluorescence emissions through an optical system of a fluorescence measuring instrument. 12. The method of claim 11 wherein P is 0.0254 at 27"C and said fluorogenic substrate is fluoroscein diacetate. 13. In the measurement of polarized fluorescence emissions from a suspension of fluorescing cells in a substrate which contributes background fluorescence a method for compensating for said background fluorescence without separating said fluorescing material from said substrate, said method comprising: a«, measuring horizontally and vertically polarized fluorescence emissions from said suspension, said measurements being taken at a first wavelength and at a second wavelength within the range of wavelengths determined by the bathochromic shift of said fluorescence emission spectrum due to extracellular fluorescence emissions and obtaining therefrom the total fluoresence emission of said suspension at each of said wavelengthsin accordance with the following relationship; ∑ total = I + 2 ( IH X G ) wherein Iy and I H are the vertically and the horizontally polarized fluorescence emission intensities and G is a correction factor for the unequal transmission of said vertically and said horizontally polarized fluorescence emissions through an optical system of a fluorescence measuring instrument; b. determining a factor representing the fraction of said total intensity of said fluorescence emission due to extracellular fluorescence, said factor being determined according to the relationship: K - Q b F ■ K - K b a wherein K a is the mean value of the intracellular fluorescence intensity at said second wavelength divided by the intracellular fluorescence intensity at said first wavelength, Kj j is the mean value of actual measurements of extracellular fluorescence emission intensities at said first and said second wavelengths for filtrates of lymphocyte suspensions and K a and K^ are constants for the particular instrumentation utilized, c. deriving from said factor the vertically and horizontally polarized emission intensities of said extracellular fluorescence in accordance with the relationships; (11) x F Iyf = 1 + 2 (1 - P k / 1 + P) and I (il) x F f = 1 + P k ( 2 + ) x G 1 - P k where Iyf is the vertically polarized fluorescence emission at said first wavelength, I Hf _^s the horizontally polarized extracellular intensity at said first wavelength , 1^ is the total intensity of said fluorescence emissions at said first wavelength, F is said factor representing the fraction of said total intensity of said fluorescence emission due to extracellular fluorescence and P is a constant derived froJSα the relationship: X V filtrate ~ G x --Η. filtrate p = X V filtrate + G x I H filtrate where Iyfϋtrate ^ s the vertically polarized fluorescence emission intensity of said substrate from which said lymphocytes have been filtered. Infiltrate is horizontally polarized fluorescence emission intensity of said substrate from which said lymphocytes have been filtered and G is a correction factor for the unequal transmission of said vertically and said horizontally polarized fluorescence emissions through an optical system of a fluorescence measuring instrument; and d. deducting said extracellular intensities from said vertically and horizontally polarized emission intensities measured at said first wavelength to obtain the vertically and horizontally polarized emission intensities due to intracellular fluorescence and thereafter applying said intracellular fluorescence emission intensities to calculate the polarization value of said cells in said suspension. 14. In the measurement of polarized fluorescence emissions from a fluorescing material in an environment which contributes background fluorescence a method for compensating for said background fluorescence without separating said fluorescing material from said environment, said method comprising: a. measuring horizontally and vertically polarized fluorescence emissions from said material in said environment, said measurement being taken at a first wavelength and at a second wavelength within the range of wavelengths determined by the bathochromic shift of said fluorescence emission spectrum due to background fluorescence emissions and obtaining therefrom the total fluoresence emission of said fluorescing material in said environment at each of said wavelengths in accordance with the following relationship; Itotal = I V + ( I H x G) wherein ly and Ig are the vertically and the horizontally polarized fluorescence emission intensities and G is a correction factor for the unequal transmission of said vertically and said horizontally polarized fluorescence emissions through an optical system of a fluorescence measuring instrument; b. determining a factor representing the fraction of said total intensity of said fluorescence emission due to background fluorescence, said factor being determined according to the relationship: F = *b " Q wherein K a is the mean value of the fluorescence intensity of said fluorescing material in the absence of background fluorescence at said second wavelength divided by the fluorescence intensity of said fluorescing material in the absence of background fluorescence at said first wavelength, K j -, is the mean value of fluorescence emission intensities of only said background fluorescence due to said environment at said first and said second wavelengths and K a and K^ are constants for the particular instrumentation utilized, c. deriving from said factor the vertically and horizontally polarized emission intensities of said background fluorescence in accordance with the relationships; x F Iyf = ( 1) 1 + 2 (1 - P / l + P) and τ Hf = ± Δ. x F 1 + P ( 2 + * ) X G 1 - P where Iy is the vertically polarized fluorescence emission at said first wavelength, I jj f is the horizontally polarized background fluorescence intensity at said first wavelength, I(ii) is the total intensity of said fluorescence emissions at said first wavelength, F is said factor representing the fraction of said total intensity of said fluorescence emission due to background fluorescence and P k is a constant derived from the relationship: p =. τ \T filtrate ~ G x I H filtrate τ V filtrate + G x I H filtrate where Iyfiltrate -- s vertically polarized fluorescence emission intensity of said fluorogenic substrate from which said lymphocytes have been filtered, Ijifiltrate is horizontally polarized fluorescence emission intensity of said fluorogenic substrate from which said lymphocytes have been filtered and G is a correction factor for the unequal transmission of said vertically and said horizontally polarized fluorescence emissions through an optical system of a fluorescence measuring instrument; and d. deducting said extracellular intensities from said vertically and horizontally polarized emission intensities measured at said first wavelength to obtain the vertically and horizontally polarized emission intensities due to intracellular fluorescence and thereafter applying said intracellular fluorescence emission intensities to calculate the polarization value of said cells in said suspension.

Inventors: CERCEK BORIS, CERCEK LEA, CERCEK, BORIS, CERCEK, LEA
Applicants: CERCEK BORIS, CERCEK LEA, CERCEK, BORIS, CERCEK, LEA
Application year: 1987
Main classification: G01N21
IPC codes: G01N21